BAYERCROP

Bayer Cropscience Share Price

 

 

Invest in Bayer Cropscience with 3.5X leverage

Invest with MTF

Performance

  • Low
  • ₹4,490
  • High
  • ₹4,533
  • 52 Week Low
  • ₹4,217
  • 52 Week High
  • ₹6,511
  • Open Price₹4,506
  • Previous Close₹4,506
  • Volume4,889

Investment Returns

  • Over 1 Month -6.55%
  • Over 3 Month -11.6%
  • Over 6 Month -19.3%
  • Over 1 Year -25.87%

Smart Investing Starts Here Start SIP with Bayer Cropscience for Steady Growth!

Invest Now

Bayer Cropscience Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 33.4
  • PEG Ratio
  • 6.6
  • Market Cap Cr
  • 20,309
  • P/B Ratio
  • Average True Range
  • 118.86
  • EPS
  • 135.49
  • Dividend Yield
  • 2.8
  • MACD Signal
  • -91.18
  • RSI
  • 36.49
  • MFI
  • 77.62

Bayer Cropscience Financials

Bayer Cropscience Technicals

EMA & SMA

Current Price
₹4,518.90
+ 12.9 (0.29%)
pointer
  • Bearish Moving Average 16
  • Bullish Moving Average 0
  • 20 Day
  • ₹4,615.87
  • 50 Day
  • ₹4,812.11
  • 100 Day
  • ₹5,040.95
  • 200 Day
  • ₹5,241.50

Resistance and Support

4531.37 Pivot Speed
  • R3 4,680.53
  • R2 4,639.27
  • R1 4,572.63
  • S1 4,464.73
  • S2 4,423.47
  • S3 4,356.83

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Bayer, a 160-year-old global life sciences company, has been a trusted brand in India for over 125 years, advancing agriculture, public health, and sustainability. Bayer’s operations in India include crop science, pharmaceuticals, and consumer health.

Bayer Cropscience has an operating revenue of Rs. 5,571.30 Cr. on a trailing 12-month basis. An annual revenue growth of 8% is good, Pre-tax margin of 13% is healthy, ROE of 19% is exceptional. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading below to its key moving averages. It needs to take out these levels and stay above it to make any meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 56 which is a POOR score indicating inconsistency in earnings, a RS Rating of 34 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at C which is evident from recent supply seen, Group Rank of 121 indicates it belongs to a poor industry group of Chemicals-Agricultural and a Master Score of C is fair but needs to improve. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Bayer Cropscience Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-11-07 Quarterly Results & Interim Dividend
2025-08-06 Quarterly Results
2025-05-26 Audited Results & Final Dividend
2025-02-11 Quarterly Results
2024-11-13 Quarterly Results
Date Purpose Remarks
2025-11-14 INTERIM Rs.90.00 per share(900%)Interim Dividend
2025-08-07 FINAL Rs.35.00 per share(350%)Final Dividend
2024-11-28 INTERIM Rs.90.00 per share(900%)Interim Dividend
2023-11-16 INTERIM Rs.105.00 per share(1050%)Interim Dividend
2022-11-19 INTERIM Rs.100.00 per share(1000%)Interim Dividend
View Bayer Cropscience Dividend History Arrow

Bayer Cropscience F&O

Bayer Cropscience Shareholding Pattern

71.43%
7.93%
2.54%
3.8%
0.02%
9.07%
5.21%

Bayer Cropscience FAQs

Bayer Cropscience share price is ₹4,518 As on 05 December, 2025 | 10:13

The Market Cap of Bayer Cropscience is ₹20308.9 Cr As on 05 December, 2025 | 10:13

The P/E ratio of Bayer Cropscience is 33.4 As on 05 December, 2025 | 10:13

The PB ratio of Bayer Cropscience is 6.6 As on 05 December, 2025 | 10:13

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23